Article in Methods in molecular biology (Clifton, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed.
Microorganisms · 2026
Review
Advanced biomedical research · 2023
Article
4 · The record
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
5 authors.
Jhanvi Sharma *Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN, USA.
Carcia S Carson *Department of Biomedical Engineering, Vanderbilt University, Nashville, TN, USA.
Trevor DouglasDepartment of Chemistry, Indiana University, Bloomington, IN, USA.
John T WilsonDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN, USA.
Sebastian JoyceDepartment of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN, USA. sebastian.joyce@vumc.org.
Funding
Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STACIE B DUSETZINA · 1995 to 2026
$172.8M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
MOLECULAR BASIS OF CDLDL AND NATURAL T CELL FUNCTIONR01AI042284 · NIAID · VANDERBILT UNIVERSITY · PI JOYCE, SEBASTIAN · 1998 to 2013
$3.1M
Head & Neck Cancer Neoantigen Characterization & Therapeutic TargetingR01DE027749 · NIDCR · VANDERBILT UNIVERSITY MEDICAL CENTER · PI JOYCE, SEBASTIAN · 2018 to 2022
$2.3M
Molecular Basis of CD1D and Natural Killer T Cell FunctionR01AI137082 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI JOYCE, SEBASTIAN · 2019 to 2022
$2.1M
Processing and Presentation of Minor Histocompatibility Antigens that Cause GvHDR01HL121139 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI JOYCE, SEBASTIAN · 2014 to 2017
$1.6M
Engineered Nanoparticles for Protective Subunit Vaccine Delivery and DiscoveryR21AI121626 · NIAID · VANDERBILT UNIVERSITY · PI WILSON, JOHN TANNER · 2016 to 2017
$418k
Molecular Basis of CD1d1 and Natural T Cell FunctionR21AI042284 · NIAID · VANDERBILT UNIVERSITY · PI JOYCE, SEBASTIAN · 2002 to 2002
$302k
BLRD Research Career Scientist Award ApplicationIK6BX004595 · VA · VETERANS HEALTH ADMINISTRATION · PI JOYCE, SEBASTIAN · 2019 to 2025
–
Vaccinating at Mucosal Surfaces with Nanoparticle Conjugated Antigen and AdjuvantI01BX001444 · VA · VETERANS HEALTH ADMINISTRATION · PI JOYCE, SEBASTIAN · 2014 to 2022
Vaccines remain the most effective way to protect populations against deathly infectious diseases. Several disadvantages associated with the traditional vaccines that use whole pathogens have led to the development of alternative strategies including the use of recombinant subunit vaccines. Subunit vaccines are, in general, safer than whole pathogens but tend to be less immunogenic due to the lack of molecular cues that are typically found on whole pathogens. To enhance immunogenicity, the subunit antigen can be administered with adjuvants that stimulate the innate immune system as a means to steer the quality and magnitude of the adaptive immune response. Novel classes of adjuvants are formulated using particle-based platforms such as virus-like particles, liposomes, and polymeric nanoparticles. These particle-based systems present antigens in ways reminiscent of whole pathogens. Such platforms offer several advantages that include co-delivery of antigen along with innate immune stimulators in a highly immunogenic format. Here we describe our recent efforts to synthesize, characterize, and validate two promising nanoparticle-based delivery systems and demonstrate their potential to induce antigen-specific CD8
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Nano-Particulate Platforms for Vaccine Delivery to Enhance Antigen-Specific CD8 · full record | OpenQuestion